BPMC Blueprint Medicines Corp

Price (delayed)

$117.32

Market cap

$7.35B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.76

Enterprise value

$7.55B

Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company ...

Highlights
Blueprint Medicines's EPS has surged by 51% YoY and by 43% QoQ
The net income has soared by 50% YoY and by 43% QoQ
Blueprint Medicines's equity has surged by 138% QoQ but it has decreased by 25% YoY
BPMC's debt is up by 37% year-on-year
BPMC's quick ratio is down by 30% year-on-year

Key stats

What are the main financial stats of BPMC
Market
Shares outstanding
62.62M
Market cap
$7.35B
Enterprise value
$7.55B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
23.12
Price to sales (P/S)
25.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.76
Earnings
Revenue
$282.21M
EBIT
-$268.79M
EBITDA
-$246.69M
Free cash flow
-$429.98M
Per share
EPS
-$4.76
Free cash flow per share
-$6.98
Book value per share
$5.07
Revenue per share
$4.58
TBVPS
$16.86
Balance sheet
Total assets
$1.04B
Total liabilities
$727.79M
Debt
$330.11M
Equity
$310.69M
Working capital
$570M
Liquidity
Debt to equity
1.06
Current ratio
3.76
Quick ratio
3.48
Net debt/EBITDA
-0.84
Margins
EBITDA margin
-87.4%
Gross margin
95.9%
Net margin
-102.2%
Operating margin
-156.2%
Efficiency
Return on assets
-26.8%
Return on equity
-120.7%
Return on invested capital
-24.5%
Return on capital employed
-32.3%
Return on sales
-95.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BPMC stock price

How has the Blueprint Medicines stock price performed over time
Intraday
-2.64%
1 week
1.18%
1 month
12.95%
1 year
102.66%
YTD
27.19%
QTD
8.85%

Financial performance

How have Blueprint Medicines's revenue and profit performed over time
Revenue
$282.21M
Gross profit
$270.69M
Operating income
-$440.89M
Net income
-$288.29M
Gross margin
95.9%
Net margin
-102.2%
BPMC's net margin has soared by 64% year-on-year and by 50% since the previous quarter
The net income has soared by 50% YoY and by 43% QoQ
BPMC's gross profit is up by 49% year-on-year and by 14% since the previous quarter
The operating margin has increased by 43% YoY and by 20% from the previous quarter

Growth

What is Blueprint Medicines's growth rate over time

Valuation

What is Blueprint Medicines stock price valuation
P/E
N/A
P/B
23.12
P/S
25.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.76
Blueprint Medicines's EPS has surged by 51% YoY and by 43% QoQ
The price to book (P/B) is 167% higher than the 5-year quarterly average of 8.9 and 7% higher than the last 4 quarters average of 22.2
Blueprint Medicines's equity has surged by 138% QoQ but it has decreased by 25% YoY
The P/S is 42% above the last 4 quarters average of 18.5 but 22% below the 5-year quarterly average of 33.9
Blueprint Medicines's revenue has increased by 38% YoY and by 13% QoQ

Efficiency

How efficient is Blueprint Medicines business performance
Blueprint Medicines's return on sales has surged by 65% YoY and by 51% QoQ
The ROIC has increased by 49% YoY and by 44% from the previous quarter
The company's return on assets rose by 41% QoQ and by 40% YoY
BPMC's return on equity is up by 37% since the previous quarter but it is down by 20% year-on-year

Dividends

What is BPMC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BPMC.

Financial health

How did Blueprint Medicines financials performed over time
BPMC's total assets is 43% greater than its total liabilities
BPMC's quick ratio is down by 30% year-on-year
Blueprint Medicines's current ratio has decreased by 28% YoY
BPMC's debt is 6% greater than its equity
Blueprint Medicines's equity has surged by 138% QoQ but it has decreased by 25% YoY
BPMC's debt to equity has surged by 83% year-on-year but it has dropped by 58% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.